KNSA
Kiniksa Pharmaceuticals, Ltd.
KNSA offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over KNSA overall, supported by stronger valuation and stronger modeled upside.
KNSA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Healthy |
KNSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
KNSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.2x | $6.87 | -93% |
| Forward | 63x | $96.28 | — |
| Fair | 67x | $87.85 | -8.8% |
| Current | 74x | $96.28 | — |
| Expensive | 143x | $188 | +95% |
Historical ranges are pointers, not guarantees.
KNSA's PE is in its fair range at 74x. If earnings grow as analysts expect, today's price would be 63x next year's earnings.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY has the edge over KNSA in the historical PE scenario, which offers more potential upside but is not a forecast.
KNSA Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for KNSA, but weaker profitability. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over KNSA on the outlook, with more favorable profitability expectations.
KNSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.52 | +16% |
| Q3 2026 | $1.31 | +185% |
| Q2 2026 | $0.98 | +1860% |
| Q1 2026 | $0.91 | +$1.15 |
| Q4 2025 | $0.75 | +$1.35 |
| Q3 2025 | $0.46 | +$0.58 |
| Q2 2025 | $0.05 | +$0.19 |
| Q1 2025 | -$0.24 | -285% |
| Q4 2024 | -$0.60 | -400% |
KNSA's earnings per share have fallen from their peak: $1.31 over the past year, against $3.28 in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over KNSA on earnings, with more consistent year-over-year improvement.
KNSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $286M | +58% |
| Q2 2026 | $243.6M | +55% |
| Q1 2026 | $214.3M | +56% |
| Q4 2025 | $202.1M | +65% |
| Q3 2025 | $180.9M | +61% |
| Q2 2025 | $156.8M | +44% |
| Q1 2025 | $137.8M | +73% |
| Q4 2024 | $122.5M | +47% |
KNSA has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +5.7 points |
| Q2 2026 | 11% | -1.7 points |
| Q1 2026 | 14% | +4 points |
| Q4 2025 | 9.8% | +26 points |
| Q3 2025 | 13% | +22 points |
| Q2 2025 | 13% | +13 points |
| Q1 2025 | 9.6% | +30 points |
| Q4 2024 | -16% | -16 points |
KNSA's operating margin was 19% last quarter, up 5.7 points from the same quarter a year ago, near the top of its range since 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over KNSA on profitability, with a higher operating margin.
KNSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $47.4M | +44% |
| Q2 2026 | $46.5M | +67% |
| Q1 2026 | $50M | +125% |
| Q4 2025 | $53.3M | +187% |
| Q3 2025 | $33M | +$35.2M |
| Q2 2025 | $27.9M | +440% |
| Q1 2025 | $22.2M | +469% |
| Q4 2024 | $18.6M | +335% |
KNSA has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
KNSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +1.5M shares |
| 1 year | +6.1% | +4.9M shares |
| 3 years | +21% | +14.7M shares |
| 5 years | +24% | +16.3M shares |
| Available history | +57% | +30.9M shares |
KNSA has 85M diluted shares, up 6.1% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over KNSA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
KNSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -1.7x | Net Cash |
| Q1 2026 | -2.0x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -4.4x | Net Cash |
| Q2 2025 | -32.1x | Net Cash |
| Q2 2023 | -2.8x | Net Cash |
| Q1 2023 | -3.3x | Net Cash |
KNSA has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
KNSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.8 | Overbought |
| Stochastic | 85.1 | Overbought |
KNSA's weekly RSI is 80 (overbought) and its Stochastic is 85 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
KNSA PE vs Healthcare Sector
| Metric | KNSA | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 184% above |
| PE % | 54 | 29 | 25 pts above |
KNSA is trading at 74x earnings, a 184% premium to the Healthcare sector's median of 26x.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY has the edge over KNSA on valuation relative to its sector.
KNSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $83.5 | 15% above |
| 20 week MA | $76.9 | 25% above |
| 50 week MA | $59.0 | 63% above |
| 100 week MA | $43.7 | 121% above |
| 200 week MA | $30.9 | 211% above |
KNSA is in an uptrend: it's above all five of its weekly moving averages, and 211% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
KNSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.7 | $19.0 | +62% |
| 2021 | $19.0 | $13.1 | -31% |
| 2022 | $13.1 | $15.5 | +18% |
| 2023 | $15.5 | $17.5 | +13% |
| 2024 | $17.5 | $20.0 | +14% |
| 2025 | $20.0 | $42.0 | +110% |
| 2026 YTD | $42.0 | $96.3 | +129% |
KNSA has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.